
News|Articles|June 1, 2010
FDA Pipeline Preview, June 2010 (BMS-224818, Roflumilast, Prostvac, Naltrexone, IL13-PE38QQR/IL13-PE, Prochymal, AEZS-108, SBC-102, Pralatrexate, RG2833)
Recent FDA action (through, May 2010) related to BMS-224818, Roflumilast, Prostvac, Naltrexone, IL13-PE38QQR/IL13-PE, Prochymal, AEZS-108, SBC-102, Pralatrexate, RG2833
Advertisement
Complete reponse
Fast-track designation
Priority review
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Immunotherapy combination of teclistamab and daratumumab heralded as potential 'functional cure' for multiple myeloma | ASH 2025
2
The trend toward post-infusion outpatient care of patients treated with CAR-T | ASH 2025
3
Brainomix 360 e-Lung Technology speeds up PPF detection
4
IV iron treatment improves survival, increases hemoglobin levels in anemic patients with acute bacterial infection | ASH 2025
5





















































